about
Nicotine chemistry, metabolism, kinetics and biomarkersBacoside A: Role in Cigarette Smoking Induced Changes in BrainConsiderations on the use of oxymorphone in geriatric patientsLamotrigine dosing for pregnant patients with bipolar disorder.In vitro tests for predicting drug-drug interactions: the need for validated procedures.The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.Mammalian Cells Exhibit a Range of Sensitivities to Silver Nanoparticles that are Partially Explicable by Variations in Antioxidant Defense and Metallothionein Expression.Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.Antidepressant-drug interactions are potentially but rarely clinically significant.Metabolic drug interactions with newer antipsychotics: a comparative review.Drug metabolism alterations in nonalcoholic fatty liver diseaseA pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.Comprehensive variant screening of the UGT gene familyQuantitative determination of common urinary odorants and their glucuronide conjugates in human urine.Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.Clinically significant drug interactions with atypical antipsychotics.Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination.The chemical disruption of human metabolism.Pharmacokinetics of antiepileptic drugs in pregnancy.The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients.Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes.Serotonin (5-hydroxytryptamine) glucuronidation in vitro: assay development, human liver microsome activities and species differences.Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways.The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy.Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3
P2860
Q24632647-CB33C0CA-9E31-42C1-A372-6DE1DF6B018AQ26786019-EA4DA508-4E14-4E8A-A51C-48BE6C46C796Q28252394-330F6B62-5590-4763-8265-155C01ABF086Q34131260-669799D9-D295-499E-8909-4DD91AD51F05Q35060620-2B22C045-6773-4DAC-8B25-B2162EED40F5Q35129048-A680DD0C-684B-4D38-9207-1075CFF5E52CQ35236618-A46EF908-0715-45BE-B365-8C5F1A3E1198Q35956406-8E245938-1275-4860-BA5F-A1CB00CC23CBQ36018600-493D60DB-C34D-409A-9736-8EC0FC38E1AEQ36538987-AD567142-9E23-4AD2-BC6C-D44B949DFC34Q36703845-6553E96F-AB4F-4353-89AA-75D4A6B52375Q37120909-F4D2CDBD-3D37-405D-A770-F99F61385657Q37354482-390CBE30-1683-495C-8283-98DC4E8B9C76Q37418838-098BF3C5-A45C-469A-9EA9-B88A35BD92D6Q37512783-21B9FBB6-80ED-41E6-9CBF-9AD469E87193Q37873934-91CE4002-2A09-46EC-9408-E5F42F025DE0Q38156416-09028329-3E76-4BCA-B1A6-9012A903EBD7Q39149746-6B510504-AAB6-4C66-AC84-33478556D116Q39264905-BA27A861-78FD-460D-A2F1-4EAC8DE6E921Q40138489-C7857E5A-BA5E-4C01-A3FD-EFDB74729F7EQ40501892-824DC95E-6067-4420-A513-DED30081E1FCQ44197191-7B1E7904-1DB2-4194-89E4-E84F1C33EFF3Q44353598-87C5AB64-044D-4A40-AA9B-D504F5CB8440Q45259355-80A814B9-3B5D-407E-88BF-F3C46D3B7082Q48288617-F4A9F5EA-81F4-40C4-88B0-38D6DA5F76A0Q57148214-2FA3D488-B977-4B6E-B1DF-0B38A4D836FF
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Drug glucuronidation in clinical psychopharmacology
@ast
Drug glucuronidation in clinical psychopharmacology
@en
Drug glucuronidation in clinical psychopharmacology
@nl
type
label
Drug glucuronidation in clinical psychopharmacology
@ast
Drug glucuronidation in clinical psychopharmacology
@en
Drug glucuronidation in clinical psychopharmacology
@nl
prefLabel
Drug glucuronidation in clinical psychopharmacology
@ast
Drug glucuronidation in clinical psychopharmacology
@en
Drug glucuronidation in clinical psychopharmacology
@nl
P2093
P1476
Drug glucuronidation in clinical psychopharmacology
@en
P2093
C L DeVane
H L Liston
J S Markowitz
P304
P356
10.1097/00004714-200110000-00008
P407
P577
2001-10-01T00:00:00Z